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a  b  s  t  r  a  c  t
Disulfiram  (DSF)  is  currently  tested  in  several  clinical  trials  for  cancer  treatment  in combination  with  cop-
per (Cu)  ions.  Usually,  DSF  and Cu are  administered  in  two  separate  formulations.  In the  body,  DSF  and
Cu ions  form  diethyldithiocarbamate  copper  complex  [Cu(DDC)2]  which  has  potent  antitumor  activities.
However,  the “two  formulation”  approach  often  achieved  low  Cu(DDC)2 concentration  at  tumor  regions
and  resulted  in  compromised  anticancer  efficacy.  Therefore,  preformed  Cu(DDC)2 complex  administered
in  a single  formulation  will  have  better  anticancer  efficacy.  However,  the  poor  aqueous  solubility  of
Cu(DDC)2 is a significant  challenge  for  its  clinical  use.  In this  work,  a biomimetic  nanoparticle  formu-
lation  of Cu(DDC)2 was  produced  with  a novel  SMILE  (Stabilized  Metal  Ion  Ligand  complex)  method
developed  in  our  laboratory  to address  the  drug  delivery  challenges.  The  Metal-organic  Nanoparticle
(MON)  is composed  of  Cu(DDC)2 metal-organic  complex  core  and  surface  decorated  bovine  serum  albu-
min (BSA).  Importantly,  we designed  a 3D-printed  microfluidic  device  to  further  improve  the  fabrication
of  BSA/Cu(DDC)2 MONs.  This  method  could  precisely  control  the MON  preparation  process  and  also  has
great potential  for large  scale  production  of Cu(DDC)2 MON  formulations.  We  also  used  a computational
modeling  approach  to simulate  the  MON  formation  process  in the microfluidic  device.  The  optimized
BSA/Cu(DDC)2 MONs  demonstrated  good  physicochemical  properties.  The  MONs  also  showed  potent
antitumor  activities  in  the breast  cancer  cell  monolayers  as well  as  the 3D-cultured  tumor  spheroids.  The
BSA/Cu(DDC)2 MONs  also  effectively  inhibited  the growth  of  tumors  in  an orthotopic  4T1  breast  tumor
model.  This  current  study  provided  a  novel  method  to prepare  a  biomimetic  MON  formulation  for  DSF/Cu
cancer  therapy.
© 2019  Elsevier  Ltd. All  rights  reserved.
1. Introduction
Disulfiram (DSF) has been approved by the FDA for treating alco-
hol abuse for more than six decades. Recently, DSF was  repurposed
for cancer treatment due to its anticancer activities. Drug repurpos-
ing is a promising approach for drug discovery and development
[1], which could shorten the development course, reduce the risk
of failure, and save R&D costs. DSF monotherapy only demonstrated
limited efficacy, while the combination of DSF and copper ions
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(Cu2+) showed significantly enhanced anticancer activities [2,3].
Diethyldithiocarbamate (a DSF metabolite) could complex with
Cu2+ ions and generate diethyldithiocarbamate copper [Cu(DDC)2]
which is a key player that accounts for the antitumor efficacy of
DSF/Cu combination therapy [4]. In many studies including clinical
trials, DSF and Cu2+ were co-administered in separate formulations
(www.clinicaltrials.gov). DSF is rapidly metabolized and degraded
in the body [3,5]. Therefore, co-administration of DSF and Cu2+ in
two separate formulations usually yielded a very low concentration
of the active ingredient, Cu(DDC)2, in the tumor region and resulted
in only marginal anticancer efficacy. Therefore, the delivery of pre-
formed Cu(DDC)2 in a single formulation is a more effective method
to achieve a higher Cu(DDC)2 concentration in tumor and improve
the anticancer efficacy [6].
https://doi.org/10.1016/j.apmt.2019.100492
2352-9407/© 2019 Elsevier Ltd. All rights reserved.
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However, the poor aqueous solubility of Cu(DDC)2 complex
created a formidable hurdle for its clinical use. Several different
nanomedicine formulations (e.g., solid nanoparticle, liposome, and
micelle) were used to deliver Cu(DDC)2 and achieved improved effi-
cacy [6–9]. Yet, there still are some challenges to be overcome:
(1) the complicated preparation processes are incompatible with
large-scale production; and (2) many formulations only achieved
low drug concentrations and were hard to obtain the minimal drug
concentration for clinical use. Due to the lack of appropriate formu-
lations, the clinical application of this drug is very limited. There is
a great need for developing a formulation that is suitable for clinical
use.
In our previous study, we developed a Stabilized Metal Ion
Ligand Nanocomplex (SMILE) technology to prepare Cu(DDC)2
metal-organic nanoparticles (MONs). And methoxy poly(ethylene
glycol)5000-b-poly(l-lactide)5000 (PEG-PLA) was used as the stabi-
lizer [10]. The SMILE method can achieve superior yield and high
drug concentration; requires a simple formulation and preparation
process; and has excellent formulation properties. In this work,
we will prepare biomimetic albumin-decorated Cu(DDC)2 MONs
with the SMILE technology. In addition, we further improved the
SMILE technology by using a 3D-printed microfluidic device for
scalable continuous production of Cu(DDC)2 MONs. With the aid
of the microfluidic device, we could achieve precise control of the
mixing process, easily scale up the preparation process for mass
production, and thus facilitate the clinical translation and future
commercialization.
2. Materials and methods
2.1. Materials
Most chemicals and supplies used in this study were purchased
from VWR  International (Radnor, USA). D--Tocopherol polyethy-
lene glycol 1000 succinate (TPGS) was ordered from Sigma-Aldrich
and used without purification (St. Louis, USA). Cyanine5 NHS ester
was obtained from Dalian Meilun Biotechnology Co., Ltd (Dalian,
China).
2.2. Production of Cu(DDC)2 MONs with the SMILE method
2.2.1. Vortexing method
The vortexing method of preparing Cu(DDC)2 MONs was
described in our previous paper [10]. Briefly, copper chloride
(CuCl2) and sodium diethyldithiocarbamatetrihydrate (DDC-Na)
were dissolved with two BSA containing aqueous solutions, respec-
tively. Then, these two solutions were vigorously mixed by
vortexing at a molar ratio of 2:1 (DDC-Na vs CuCl2). The Cu(DDC)2
MONs formed by DDC-Na and CuCl2 were stabilized by BSA. Large
aggregations were removed by centrifugation for 10 min  at 6700 g
and followed by filtration with a 0.45 m filter. The influence of
CuCl2, DDC-Na, and BSA concentration was extensively investi-
gated.
2.2.2. Microfluidic device method
We first prepared a microfluidic mixing device with a 3D printer
(Fig. S1). The device was printed with a HICTOP Creality CR-10
3D-printer using PLA as the printing material. Then, the DDC-Na
solution and CuCl2 solution were delivered into the mixing device
through two inlets with syringe pumps (Fig. 3A). The resulting
MONs were collected from the outlet and purified by centrifugation
and filtration with the same procedure as described in the vortexing
method.
2.3. Determination of particle size, zeta potential, and
morphology
2.3.1. Particle size and zeta potential
The particle size and polydispersity index (PDI) were deter-
mined with Malvern Nano ZS based on the dynamic light scattering
[11]. The MONs were diluted with water before measurement. The
particle size and PDI were determined at 173-degree scattering
angle. The zeta potential was also determined with the Malvern
Nano ZS.
2.3.2. Transmission Electron Microscope (TEM)
To characterize the MONs with TEM, samples were first added
onto a grid and followed by uranyl acetate staining [12,13]. Then,
samples were observed under a JEOL 2000EX Transmission Electron
Microscope (Tokyo, Japan).
2.4. Determine drug concentration and yield
Drug concentrations in NP formulations were determined with
the UV–vis spectrophotometric assay. Briefly, formulations were
dissolved in dimethylformamide (DMF). The concentration of
Cu(DDC)2 was  determined by the absorbance at 435 nm and cal-
culated with the standard solution of Cu(DDC)2 dissolved in DMF.
The yield was calculated with this equation:
Yield (%) = (Actual Drug Concentration /Theoretical
Drug Concentration)  × 100% (1)
2.5. Stability
To determine the influence of serum on stability, the MON  for-
mulations were mixed with fetal bovine serum (FBS) solution (10%
w/v) and incubated at a temperature of 37 ◦C. Then, at different time
points, the particle size and PDI were measured. To determine long-
term storage stability, the MON  formulations were stored at room
temperature (25 ◦C) or refrigerator (4 ◦C). Cu(DDC)2 concentrations
were determined at different days.
2.6. Modeling of MON  formation process in the microfluidic
device
The fluid within the microfluidic device is incompressible New-
tonian fluid, and we  further assume that the fluid properties such
as density and viscosity are constants and independent of the con-
centration of the formed MONs. Under steady-state, the flow is
described by the Navier–Stokes equations and the continuity equa-
tion:
(u · ∇)u = −∇p + ∇ · (∇u + (∇u)T ), (2)
∇ · u = 0. (3)
In the above, u is the fluid velocity, p is the fluid pressure,  and 
are, respectively, viscosity and density of the fluid.
The concentrations of the species, DDC-Na, CuCl2, and the




+ u · ∇ci = Di∇2ci + Ri, (4)
Where ci, Di and Ri are, respectively, the molar concentration, dif-
fusion coefficient, and rate of reaction of the ith species (i = 1 for
DDC-Na, 2 for CuCl2, and 3 for Cu(DDC)2). The reaction rates of the
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irreversible chemical reactions 2 DDC-Na + CuCl2 → Cu(DDC)2 + 2
NaCl2 are given by:
R1 = R2 = –R3 = –kc1c2, (5)
with the rate constant, k, determined based on the Arrhenius equa-
tion.
For the steady-state Navier-Stokes equations, constant flow
rates of 0.5, 1, and 2 mL/min, respectively, were imposed at the
two inlets. Non-slip boundary condition (i.e., u = 0) was  imposed
on the solid microfluidic channel wall, and outflow with pressure
p = 0 was applied at the outlet.
For the time-dependent convection-diffusion equations, the
concentrations of CuCl2 and DDC-Na of the two  inlets were
11 mmol/L and 22 mmol/L, respectively, and the other rigid bound-
aries were non-flux boundaries. At the outlet, n · Di∇ci = 0 was
set for the concentration of the ith species. At time = 0, the ini-
tial condition for each species within the microfluidic channel
has zero concentration. In this study, we set the density  =
2000 kg/m3, dynamic viscosity  = 0.001 Pa · s, diffusion coeffi-
cients the ith (i = 1,2 and 3) species are, respectively, 1 × 10−9 m2/s,
1 × 10−9 m2/s, and 1 × 10-10 m2/s. We  first solve the steady-
state Navier Stokes equations by using the commercial finite
element package, Comsol (www.comsol.com), installed in a high-
performance cluster. With the known flow field, we solve the
time-dependent convection-diffusion-reaction equations for the
concentrations of the species.
2.7. MTT  assay
4T1 mouse breast cancer cells were obtained from the American
Type Culture Collection (ATCC). The culture medium was Roswell
Park Memorial Institute (RPMI) 1640 containing 1% Antibiotic-
Antimycotic and 10% FBS. MD  Anderson-Metastatic Breast-231
(MDA-MB-231) cells (ATCC) were cultured with a mixture of Ham’s
F-12 Medium and Dulbecco’s Modified Eagle’s Medium (DMEM)
(1:1) containing 1% Antibiotic-Antimycotic and 10% FBS. Cells were
cultured in a humidified incubator with 5% CO2 at 37 ◦C.
To test cytotoxicity, cells were seeded into a 96-well plate
(5000 cells/well) and incubated overnight to allow cells to attach
to the plate. Then, different test agents with various concentra-
tions were diluted with cell culture medium and added into wells
(100 L/well). At the end of treatment, cytotoxicity was  determined
with 3-(4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bro-
mide (MTT) assay [12,14–17]. The absorbance was  determined at
570 nm and subtracted by the reference absorbance at 670 nm.  The
following equation was used to calculate the cell viability:
Cell Viability(%) = (ATest/Acontrol) × 100%
GraphPad Prism software was used to calculate the IC50.
2.8. Calcein-AM/Propidium Iodide (PI) staining
Cells were added into a 96-well plate at a density of 10,000
cells/well one night before experiment. Then, cells were treated
for 24 h with different formulations and followed by Calcein-AM
and PI staining. The staining solution was prepared by diluting
Calcein-AM and PI stock solutions in pH 7.4 phosphate-buffered
saline (PBS). Both dead cells with red fluorescence and viable cells
with green fluorescence will be analyzed with the Cytation 5 Cell
Imaging Multi-Mode Reader.
2.9. Penetration and cytotoxicity on tumor cell spheroids
Tumor spheroids were established with a liquid overlay method
[18]. Briefly, 4T1 cells were seeded in a 96-well plate pretreated
with agarose gel (1% w/v). After 7 days of culture, spheroids were
treated with various testing formulations for 72 h. The morphol-
ogy of spheroids was  recorded with microscopy. The cytotoxicity
was determined with the Calcein-AM/Propidium Iodide (PI) stain-
ing method as well as CellTiter-Blue reagents (Promega). For the
Calcein-AM/Propidium Iodide (PI), tumor spheroids were incu-
bated with a staining solution containing PI (3M) and Calcein-AM
(3M) in pH 7.4 phosphate-buffered saline (PBS) at 37 ◦C for
30 min. Both dead cells with red fluorescence and viable cells with
green fluorescence will be analyzed with the Cytation 5 Cell Imag-
ing Multi-Mode Reader. For the CellTiter-Blue reagent assay, the
CellTiter-Blue reagents were mixed with treated tumor spheroids
and incubated for 24 h. At the end of incubation, the fluores-
cence intensity was  determined with the Cytation 5 Cell Imaging
Multi-Mode Reader (EX560 nm and EM590 nm). To determine pen-
etration ability of the nanoparticles in tumor spheroids, cyanine
5 (Cy5)-labeled BSA Cu(DDC)2 MONs were synthesized as previ-
ously reported [7] and incubated with tumor spheroids for 3 h at
37 ◦C. At the end of incubation, spheroids were then rinsed with
PBS three times and analyzed with confocal microscopy (TCS-SP8,
Leica, Germany).
2.10. Would healing study
The 4T1 or MDA-MB-231 cells were seeded at a 96-well plate at
a density of 10,000 cells/well and cultured at 37 ◦C overnight before
test. Scratch on the cell monolayer was created with a 10 L pipette
tip. Then, cells were treated with different formulations for 18 h.
Cell migration distance was determined by comparing the scratch
width at the end of treatment with the initial scratch width.
2.11. In vivo orthotopic breast tumor model, biodistribution, and
anticancer efficacy study
Balb/c mice (female, 4 weeks) were purchased from the Shang-
hai Laboratory Animal Center (SLAC) Co., Ltd. (Shanghai, China).
Animals were housed at the SPF care facility under a 12 h light/dark
cycle with distilled water and sterilized food pellets. Animal study
protocols were approved by the Institutional Animal Care and
Use Committee (IACUC) of SIMM and performed in accordance
with the Guidelines for Care and Use of Laboratory Animals of
Shanghai Institute of Materia Medica (SIMM), Chinese Academy
of Sciences. The animal models with orthotopic breast tumors
were established by injecting 4T1 cells (1 × 106 cells) into the sec-
ond mammary fat pad of the Balb/c mice [18]. Treatments were
initiated when the tumors were reached an average volume of
80–90 mm3. Tumor size (mm3) = [width (mm)2 × length (mm)] ×
1/2. Mice were randomly divided into six groups (5 mice per group)
and received intravenous administration of Cu(DDC)2 solution
containing 10% (2-Hydroxypropyl)--cyclodextrin and 5% ethanol
(3 mg/Kg Cu(DDC)2), BSA Cu(DDC)2 MONs (1.5 mg/Kg Cu(DDC)2),
and BSA Cu(DDC)2 MONs (3 mg/Kg Cu(DDC)2), and equivalent
dose of BSA, CuCl2 aqueous solution, DDC-Na aqueous solution.
Mice received a total of three treatments on day 7, 10, and 13,
respectively. Body weight and tumor volume were monitored and
recorded. At the end of the experiment, the mice were euthanized
and the weight of collected tumors was  determined. For biodistri-
bution studies, the orthotopic 4T1 tumor-bearing BALB/c female
mice were injected with Cy5-conjugated BSA Cu(DDC)2 MONs via
the tail vein. Then, in vivo imaging was conducted using an IVIS sys-
tem (Caliper PerkinElmer, Hopkinton, USA) at predetermined time
points. At the experimental endpoint, the mice were sacrificed, and
the tumors and major organs were harvested for ex vivo imaging.
The excitation wavelength was  set at 640 nm, and the emission
wavelength at 680 nm.
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3. Results
3.1. Preparation and physicochemical characterization of
Cu(DDC)2 MONs
In our previous study, we developed SMILE technology to
prepare Cu(DDC)2 MONs with different amphiphilic molecules
including methoxy poly(ethylene glycol) 5000 -b-poly(L-lactide)
5000 (PEG-PLA), TPGS, and 1, 2-distearoyl-sn-glycerol-3-
phosphoethanolamine-poly(ethylene glycol) 2000 (DSPE-PEG).
In the current study, BSA was explored as a stabilizer to prepare
biomimetic Cu(DDC)2 MONs with the same SMILE method. Of
note, the decorated albumin can also serve as a targeting ligand
to bind with albumin-binding proteins (e.g., SPARC) that are
overexpressed in the tumor cells [7,8,19–21]. When Cu2+ (a metal
ion) was mixed DDC− (an organic ligand), they formed insoluble
Cu(DDC)2 metal-organic complex. The DDC- and Cu2+ form com-
plex at a mole ratio of 2:1 (Fig. 1A). BSA could effectively stabilize
the in situ formed Cu(DDC)2 MONs and prevent the formation of
large aggregations. The formation of Cu(DDC)2 was  confirmed by
the appearance of a specific peak at 435 nm.  At the same time, a
specific peak for DDC-Na at around 375 nm disappeared (Fig. 1C).
The Cu(DDC)2 MONs have a dark brown color which was due to
the color of Cu(DDC)2 complex, while both DDC- and Cu2+ were
transparent without any obvious color (Fig. 1B). The formation
of MONs was further confirmed by determining particle size
with dynamic light scattering and TEM. The particle size of BSA
Cu(DDC)2 MONs was around 63 nm while the particle size of free
BSA molecule was around 3 nm (Fig. 1E). Both of them have similar
negative zeta potentials (Fig. 1D). The TEM results also confirmed
the morphology and size of BSA Cu(DDC)2 MONs, which was
consistent with the particle size determined with the dynamic
light scattering (Fig. 1F).
To optimize the formulation, we produced BSA Cu(DDC)2 MONs
with different BSA concentrations and theoretical drug concen-
trations. The yield and actual drug concentration of these MON
formulations were determined (Fig. 2A & B, Tables S1 & S2). At
the theoretical drug concentration of 0.5 mg/mL, we  could suc-
cessfully produce Cu(DDC)2 MONs with BSA at the concentration
from 0.1% to 4%. The yield was around 100% in all groups and
actual drug concentration was around 0.5 mg/mL. At the theoretical
drug concentration of 1 mg/mL, we could also successfully produce
Cu(DDC)2 MONs with BSA at the concentration from 0.5% to 4% with
yield around 100% and actual drug concentration about
1 mg/mL. The yield was reduced to around 83% when the BSA
concentration was 0.1%. At the theoretical drug concentration of
2 mg/mL, Cu(DDC)2 MONs could be prepared at BSA concentration
of 1%, 2%, and 4%, respectively. The yield was above 90% and actual
drug concentration was around 2 mg/mL. The yield was reduced
to 69% and 29% when BSA concentration was 0.1% and 0.5%. In
summary, BSA is an excellent stabilizer for preparing Cu(DDC)2
MONs. The yield was dependent on the concentration of BSA and
Cu(DDC)2. We  could successfully prepare MONs at a wide range
of Cu(DDC)2 concentrations at high concentration of BSA. When
the BSA concentration was low, we could only prepare MONs at
low Cu(DDC)2 concentrations. We  also determined the particle
sizes and PDI of Cu(DDC)2 MONs prepared with different BSA con-
centrations and theoretical drug concentrations (Fig. S2 A & B,
Table S3 &S4). We  could successfully prepare Cu(DDC)2 MONs with
sizes less than 100 nm at most of the tested conditions. Both the
Cu(DDC)2 theoretical concentration and BSA concentration showed
significant influence on particle size. When the theoretical drug
concentration increased from 0.5 mg/mL  to 2 mg/mL, the particle
size increased accordingly at all groups with different BSA con-
centrations. At the theoretical drug concentration of 0.5 mg/mL,
particle decreased with increased BSA concentration. At the the-
oretical drug concentration of 1 mg/mL  or 2 mg/mL, the particle
size decreased first and then slightly increased with the increase of
BSA concentration. The smallest particle size of these two groups
was achieved at BSA concentration of 1%. Based on these results,
we decided to use theoretical drug concentration 2 mg/mL  and 1%
BSA as the condition to prepare BSA Cu(DDC)2 MONs in our studies
unless otherwise specified. The MONs will be prepared with DDC-
Na solution [0.011 mmol/mL  DDC-Na and 1% (w/v) BSA] and CuCl2
solution [0.022 mmol/mL  CuCl2 and 1% (w/v) BSA].
The vortex mixing method is a convenient approach to pro-
duce Cu(DDC)2 MONs at a small scale in the research laboratory. A
large scale production method is needed for clinical translation or
commercialization. Therefore, we  developed a microfluidic device
to prepare Cu(DDC)2 MONs. This method could improve the mix-
ing process and could be scaled up to produce MONs on a large
scale. In this study, we  used a microfluidic device to produce BSA
Cu(DDC)2 MONs (Fig. 3A). The microfluidic device was fabricated
with a 3D printer. Our results showed that this microfluidic device
could successfully produce MONs at the theoretical drug concen-
tration of 2 mg/mL  and 1% of BSA as the stabilizer. The effects of
flow rate on BSA Cu(DDC)2 MON  drug concentration and particle
size were investigated (Fig. 3B&C). The flow rate had a significant
influence on final drug concentration and drug loading efficacy of
Cu(DDC)2 MONs. When the flow rate increased from 0.5 mL/min
to 2 mL/min, the drug concentration in the MONs increased from
1.3 mg/mL  to 1.9 mg/mL  and the yield increased from 66% to 95%.
The increase in flow rate might lead to a better mixing process,
more efficient MON  formation, and thus a higher drug concentra-
tion and yield. MONs prepared under different flow rate showed
similar particle sizes (around 65 nm)  and PDI values (around 0.2).
At the optimized condition, Cu(DDC)2 MONs prepared with the
microfluidic device showed a similar drug concentration and par-
ticle size as those prepared with the vortex method with the same
formulation. (i.e., 1% BSA, 2 mg/mL  Cu(DDC)2 theoretical concen-
tration). To further understand the mixing and MON  formation
process, a computational modeling approach was used to simu-
late this process. The simulation results also revealed the influence
of flow-rate on Cu(DDC)2 MON  concentrations and demonstrated
a good correlation with the experimental data (Fig. 3D). Accord-
ing to the simulation data, the concentration of Cu(DDC)2 MONs
increased with increased flow rate from 0.5 ml/min to 2 ml/min.
Also, the concentration of MONs increased during the mixing pro-
cess when the reaction mixture was moving forward in the channel
of the microfluidic mixing device (Fig. 3D).
To predict the in vivo stability of Cu(DDC)2 MONs, we incu-
bated MON  formulations with serum and determined the change
of particle size. We  tested the stability of three formulations: 1)
the BSA/Cu(DDC)2 MONs prepared with the vortex method, 2) the
BSA/Cu(DDC)2 MONs prepared with the microfluidic device, and
3) the TPGS/Cu(DDC)2 MONs prepared with the vortex method
(Fig. 4A). The BSA/Cu(DDC)2 MONs showed almost no significant
change in particle size during the incubation with serum for up to
57 h, indicating its excellent stability. In addition, the BSA/Cu(DDC)2
MONs prepared with the vortexing method demonstrated a similar
stability performance. In contrast, the TPGS/Cu(DDC)2 MONs were
less stable than the BSA/Cu(DDC)2 MONs, showing a significant
increase in particle size after 5 h of incubation.
The long-term storage stability of different MON  formulations
at the room temperature (25 ◦C) and in the refrigerator (4 ◦C) were
also determined. When kept at the room temperature, a signifi-
cant amount of precipitation was observed in the TPGS/Cu(DDC)2
MON  group and the drug concentration was also declined dramat-
ically within one week. In contrast, the BSA/Cu(DDC)2 MON  groups
showed excellent storage stability. No obvious precipitation or a
significant decrease in drug concentration was observed for over
50 days (Fig. 4B). When stored at 4 ◦C, the BSA/Cu(DDC)2 MON
Y. Chang, J. Jiang, W.  Chen et al. / Applied Materials Today 18 (2020) 100492 5
Fig. 1. Characterization of BSA Cu(DDC)2 MONs.  (A) Schematic illustration to show the Cu(DDC)2 complex formation. (B) Photos of Cu(DDC)2 MONs, DDC-Na and CuCl2. (C)
The spectrum of Cu(DDC)2 solution, DDC-Na, CuCl2, and Cu(DDC)2 MONs. (D) Zeta potential. (E) Particle Size. (F) TEM of BSA Cu(DDC)2 MONs.
groups also demonstrated good stability. Although the stability of
the TPGS/Cu(DDC)2 MON  was improved at 4 ◦C, there was still a sig-
nificant decrease in drug concentration during long-term storage
(Fig. 4C).
3.2. Anticancer activity of Cu(DDC)2 MONs
The anticancer activity of the BSA/Cu(DDC)2 MONs were deter-
mined with the MTT  Assay using two different breast cancer cell
lines: MDA-MB-231 and 4T1(Fig. 5). Cells were treated with differ-
ent formulations for 48 h before the MTT  assay. For MDA-MB-231
cell, the IC50 of BSA/Cu(DDC)2 MONs is 200 nM.  In contrast, CuCl2,
DDC-Na monotherapy did not show significant toxicity on MDA-
MB-231 cells at the tested concentrations (up to 1 M).  (Fig. 5).
Similar anticancer efficacy was observed in 4T1 cells. The IC50 of
the BSA/Cu(DDC)2 MONs was 170 nM on 4T1 cells.
We also determined the viability of MDA-MB-231 and 4T1 cells
treated with the BSA/Cu(DDC)2 MONs using the Calcein AM and PI
staining (Fig. 6). The portion of dead cells with red staining (PI) was
higher at a higher drug concentration. Concurrently, the living cells
with green fluorescence (Calcein AM)  decreased with increased
drug concentrations. We  also observed that dose-dependent reduc-
tion in the number of attached cells due to the detachment of
dead cells after the treatment. This is consistent with a previous
report which indicated disulfiram/Cu induced cell detachment due
to anoikis [22].
The anticancer efficacy was  also tested with 3D-cultured 4T1
tumor spheroids. As shown in Fig. 7A, the majority of the cells of
tumor spheroids were living cells with green staining when treated
with CuCl2 or DDC-Na. Tumor spheroids treated with BSA Cu(DDC)2
MONs had less number of living cells and more dead cells. The via-
bility of tumor spheroids was also determined with CellTiter-Blue
reagents which showed similar results as demonstrated in the Cal-
cein AM/PI staining experiment (Fig. 7B). Tumor spheroids treated
with the BSA/Cu(DDC)2 MONs showed significantly reduced cell
viability. In contrast, the DDC-Na treated group showed a slight
decrease in cell viability and CuCl2 treated group showed almost
no change of cell viability compared with the untreated control.
The treatment of the BSA/Cu(DDC)2 MONs also caused a signif-
icant change in tumor spheroids morphology (Fig. S3). Tumor
spheroids treated with CuCl2 or DDC-Na remained as intact round-
shaped spheroids. In contrast, those treated with BSA/Cu(DDC)2
MONs demonstrated compromised integrity with a large number
of detached cells at the edge of spheroids.
We  also tested the penetration ability of Cu(DDC)2 MONs in
tumor spheroids. The results showed that Cu(DDC)2 MONs could
penetrate the tumor spheroids and the penetration depth was
around 30 m (Fig. S5). The Cu(DDC)2 drug release from pene-
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Fig. 2. Formulation optimization. The effects of BSA concentrations and theoretical drug concentrations on (A) drug concentration and (B) yield of BSA Cu(DDC)2 MONs.
Results  are the mean (n = 3).
trated MONs could further diffuse into the tumor spheroids and
kill additional neighboring tumor cells.
The would-healing study was performed to test the effects of the
BSA/Cu(DDC)2 MON  on cell migration. Cell scratch was made on the
4T1 cell monolayer and then cells were treated with CuCl2, DDC-
Na, and the BSA/Cu(DDC)2 MON  (Fig. 8). CuCl2 and DDC-Na did not
have a significant effect on the cell migration towards the scratch
and the gap was similar as observed in the untreated control group.
BSA/Cu(DDC)2 MONs significantly inhibited the cell migration and
had a relatively large gap. Similar results were also observed in
MDA-MB-231 cells (Fig. S4).
In vivo anticancer efficacy and biodistribution study was carried
out in the orthotopic 4T1 breast tumor-bearing mice. Different for-
mulations were administered through intravenous injection. The
biodistribution results showed enhanced accumulation of MONs in
the tumor region (Fig. 9). The accumulation of MONs in the tumor
could be observed as early as 0.5 h post injection. The highest level
was achieved around 8–12 h post injection. The signal was still
detectable after 24 h. Ex vivo imaging also confirmed the accumu-
lation of MONs in tumor regions. We  also observed distribution of
MONs in other organs such as liver, lung, and kidney at lower levels.
The treatment of the BSA/Cu(DDC)2 MONs at a dose of 3 mg/kg
resulted in significant inhibition of tumor growth (Fig. 10A), while
no significant anticancer efficacy was observed in groups treated
with BSA Cu(DDC)2 (1.5 mg/kg), Cu(DDC)2 solution (3 mg/kg), and
equivalent dose of CuCl2 solution, or DDC-Na solution. At the end
of the study, tumors were collected and weighted (Fig. 10B&D).
Among them, the BSA/Cu(DDC)2 MON  (3 mg/kg) group showed the
most potent anticancer efficacy among all treatment groups. The
body weight of tumor-bearing mice was also monitored continu-
ously as an indication of acute systemic toxicity. The body weight of
mice in all test group increased slightly during the course of in vivo
experiment and no dramatic change of body weight was  observed,
indicating good tolerance of formulations (Fig. 10C).
4. Discussion
Multiple different methods were investigated in previous stud-
ies to prepare nanoscale metal-organic materials. These methods
include solvo/hydrothermal synthesis, ultrasound-assisted syn-
thesis, microwave-assisted synthesis, mechanochemical synthesis,
reverse-phase emulsion, and liposome-based method [23]. In this
work, we  used a SMILE method and 3D-printed microfluidic device
to prepare the BSA/Cu(DDC)2 MONs as a novel formulation for
DSF/Cu combination therapy. For this method, the nanoparticles
were prepared by mixing Cu2+ (a metal ion) with DDC− (a ligand)
in aqueous solution in the presence of BSA stabilizer. According to
a Lamer model, the MONs formation process includes two critical
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Fig. 3. Production of BSA Cu(DDC)2 MONs with a microfluidic device. (A) Schematic illustration to show the preparation of BSA Cu(DDC)2 MONs. The effects of flow rate on
(B)  drug concentration and yield, and (C) particle size and PDI. (D) Computational modeling to simulate the effect of flow rate on the MON  formation. Cu(DDC)2 concentration
C0 surface plot on the outlet cut cross plane for different flow rate (I) 0.5 mL/min, (II) 1 mL/min, and (III) 2 mL/min, respectively. (IV) The simulated Cu(DDC)2 concentration
C0 versus the distance from mixing start point.
steps: (1) homogenous nucleation formation; and (2) termination
of nucleation by rapid reduction of precursor concentration. The
rapid nucleation process is critical for the synthesis of uniform NPs
[24,25]. In the current study, the rapid mixing and reaction between
Cu2+ and DDC− is essential for the preparation of BSA Cu(DDC)2
MONs.
In the current study, we designed a prototype 3D-printed
microfluidic device to produce BSA-Cu(DDC)2 MONs. It is a sim-
ple passive microfluidic mixing device with zigzag channels. The
BSA-Cu(DDC)2 MONs prepared with this device showed a small
sub-100 nm nanoparticle size and had a narrow size distribu-
tion. The use of the microfluidic mixing device is an efficient
method to achieve rapid and thorough mixing of samples [26].
The rapid mixing of Cu2+, DDC−, and BSA stabilizer in the mixing
device contributed to the efficient production of Cu(DDC)2 MONs.
With the optimized condition, a high yield of MON  production
(95%) was achieved in the current study. The passive microflu-
idic mixing devices require no extra external energy. The mixing
process relies mainly on chaotic advection effects or enhanced
molecular diffusions. Besides the zigzag channel design used in
the current study, there are multiple other passive microfluidic
mixing devices which have 3-D serpentine structure, embedded
barriers, or twisted channels. Furthermore, active mixing devices
could also be used to enhance the mixing process by external
forces such as acoustic/ultrasonic, dielectrophoretic, electroki-
netic time-pulsed, electrohydrodynamic force, thermal actuation,
magneto-hydrodynamic flow, and electrokinetic instability [26].
The microfluidic device used in the current study showed out-
standing performance in the fabrication of BSA-Cu(DDC)2 MONs.
If needed, microfluidic mixing devices with sophisticated designs
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Fig. 4. Stability of Cu(DDC)2 MONs. (A) MONs prepared with different methods were treated with 10% serum. Particle size was determined at different time points. Stability
of  Cu(DDC)2 MONs at 25 ◦C (B) and 4 ◦C (C). Cu(DDC)2 concentration was  determined at different days. Results are the mean ± SD (n = 3).
Fig. 5. MTT  assay. (A) MDA-MB-231 and (B) 4T1 cells were treated with different formulations for 48 h and analyzed with the MTT  assay. Results are the mean ± SD (n = 4).
Fig. 6. Calcein-AM/PI staining. (A) 4T1 cells were treated with BSA Cu(DDC)2 MONs for 18 h. (B) MDA-MB-231 were treated with BSA Cu(DDC)2 MONs for 48 h. Then, cells
were  stained with Calcein-AM (green) and PI (red) at the end of drug treatment.
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Fig. 7. Effects of BSA Cu(DDC)2 MONs on 4T1 cell tumor spheroids. Tumor spheroids were treated with CuCl2 (1M),  DDC-Na (2M),  and BSA Cu(DDC)2 MONs (1M)  for
72  h. At the end of treatment, tumor spheroids were analyzed with (A) Calcein-AM/PI staining, and (B) CellTiter-Blue Cell Viability Assay. Results are the mean ± SD (n = 3).
***,  P < 0.001, and **, P < 0.01.
Fig. 8. Would-healing study.  After generation of the scratch, 4T1 cells were treated with control, CuCl2 (0.2 M),  DDC-Na (0.4 M),  and BSA Cu(DDC)2 MONs (0.2 M)  for
18  h. Photos were taken at 0 h and 18 h, respectively.
may  be used to further improve the mixing process and the pro-
duction of MONs.
The “vortexing method” is a convenient approach to prepare
Cu(DDC)2 MONs on a small scale. However, it will be challenging
to produce a large amount of MONs with the “vortexing method”. To
address this challenge, we developed a microfluidic device- based
method for scalable continuous production of MONs. The proto-
type device used in this study could produce 240 mL  Cu(DDC)2
MONs (2 mg/mL) per hour. This method is much more efficient than
“vortexing method” which usually produces 1 mL  Cu(DDC)2 MONs
per batch. The production efficiency of microfluidic device method
could be further increased by adjusting the design of device. For
example, multiple mixing units could be integrated into one single
device and produce nanoparticles in parallel [27]. Because of the
simple formulation and scale-up friendly preparation procedure,
the use of microfluidic device for preparing Cu(DDC)2 MONs will
have a great potential for clinical translation and commercializa-
tion.
Inspired from nature, a biomimetic delivery system was  devel-
oped utilizing components of biological systems to improve the
drug delivery performance [18,28,29]. In this study, we  selected
BSA as a stabilizer which could stabilize Cu(DDC)2 MONs and min-
imize the number of large aggregations. The amino acid residues of
BSA (e.g., Lys 199) could form coordination interactions with tran-
sition metal ions [30]. Therefore, BSA could effectively attach to the
surface of Cu(DDC)2 MONs through its strong interaction with Cu2+
and form a protective corona on the surface of MONs. This method
has significantly enhanced the stability of Cu(DDC)2 MONs. The
biomimetic surface functionalization of MONs with BSA will also
improve the in vivo biocompatibility.
Albumin-based biomimetic nanoparticle formulation also has
great potential for tumor-targeted drug delivery. For exam-
ple, Abraxane is a paclitaxel-albumin nanoparticle formulation
approved by the FDA for chemotherapy. The albumin nanoparticle
formulation could enhance drug delivery into tumors through the
secreted protein acidic and rich in cysteine (SPARC) receptor [31].
SPARC is an albumin binding protein overexpressed in cancer cells
and tumor vessel endothelial cells. The active recruitment of albu-
min  by tumor microenvironment could be utilized as a method for
tumor-targeted drug delivery. The biodistribution results showed
enhanced accumulation of BSA Cu(DDC)2 MONs in the tumor region
(Fig. 9). The BSA-Cu(DDC)2 MONs may  target tumors through
enhanced permeability and retention (EPR) effects and the secreted
protein acidic and rich in cysteine (SPARC) receptor mediate cel-
lular uptake [31]. We  could further improve the tumor targeting
and reduce the distribution in normal tissues and organs through
functionalizing the surface of BSA-Cu(DDC)2 MONs with additional
tumor-targeting moieties. The albumin bears functional groups
which could be used to conjugate tumor-targeting moieties [7,8].
We are in the process of functionalizing albumin with active tumor-
targeting ligands which will further enhance the tumor-targeting
and improve anticancer efficacy. The efficient intratumor penetra-
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Fig. 9. In vivo biodistribution of Cy5-labeled BSA Cu(DDC)2 MONs in mice with 4T1 orthotropic tumors determined with bioimaging. (A) The whole-body imaging at different
time  post injection. (B) Ex vivo imaging of isolated organs (heart, liver, spleen, lung, kidneys) and tumor. (C) The in vivo radiant efficiency of the tumor sites. Results are the
mean  ± SD (n = 3).
tion of nanoparticle are critical for their anticancer efficacy. We
determined the penetration ability of BSA Cu(DDC)2 MONs with
in vitro tumor spheroids. Although the penetation depth was  not
deep enough reach the core of tumor spheroids, the Cu(DDC)2
drugs released from penetrated MONs could further diffuse into
the tumor spheroids and kill additional neighboring tumor cells.
Also, we could further optimize the physicochemical properties of
Cu(DDC)2 MONs (e.g., size, charge, and surface chemistry) or use
other strategies to further enhance the penetration ability which
will further improve the anticancer activities.
In this study, we used an in vitro wound healing study to deter-
mine the effects of drug treatment on cell migration which is a
critical step for cell invasion and metastasis [22,32]. The effects of
disulfiram (DSF) or DSF/Cu combination treatment on cell migra-
tion have been tested in several previous studies by wound healing
study [22,33,34]. A recent study reported that the DSF/Cu treatment
caused the down-regulation of focal adhesion kinase (FAK) [22].
The FAK is an important molecule of focal adhesion and associated
with breast cancer metastasis [35]. Therefore, the Cu(DDC)2 MONs
which is nanoparticle formulation for DSF/Cu combination therapy
might inhibit cell migration through the inhibition of FAK. Due to
the clinical significance of tumor metastasis, it will be interesting to
further explore the effects of BSA Cu(DDC)2 MONs on the preven-
tion of breast cancer metastasis with additional in vitro and in vivo
studies. In the current study, we  used a murine 4T1 tumor to test the
in vivo anticancer efficacy. It is a widely used breast cancer model
for testing the anticancer efficacy. However, the 4T1 tumor model
is a very aggressive tumor model with rapid growth. The humane
endpoint was  reached in a relatively short period of time. Many
other previous studies used 4T1 tumor model also showed short
duration of study [36–38]. In the future, we  will test BSA Cu(DDC)2
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Fig. 10. In vivo anticancer studies. (A) Change of tumor volume in 4T1 tumor-bearing mice received intravenous injection of different formulation (**, P < 0.01, 3 mg/kg BSA
Cu(DDC)2 MONs Vs 1.5 mg/kg BSA Cu(DDC)2 MONs; ***, P < 0.001, 3 mg/kg BSA Cu(DDC)2 MONs Vs other groups). (B) Tumor weight measured at the end of the study (***,
P  < 0.001, **, P < 0.01, compared with 3 mg/kg BSA Cu(DDC)2 MONs). (C) Photos of collected tumor tissues. (D) Change of body weight in 4T1 tumor-bearing mice during the
course of study. Results are the mean ± SD (n = 5).
MONs in different tumor models which will allow us to observe
long-term effects.
5. Conclusion
In conclusion, we designed a 3D-printed microfluidic device
to prepare BSA Cu(DDC)2 MONs with a SMILE technology devel-
oped in our lab. The optimized formulation has a small particle
size (<100 nm)  and narrow size distribution. The biomimetic MONs
prepared with BSA as a stabilizer demonstrated excellent stabil-
ity in serum and during long-term storage. The BSA Cu(DDC)2
MONs demonstrated great potentials for treating breast cancers.
To further develop the formulation, we will perform additional pre-
clinical studies to extensively explore the in vivo pharmacokinetics,
safety, and anticancer efficacies.
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